COVID-19 mRNA vaccine-related interstitial lung disease: Two case reports and literature review.
COVID‐19
interstitial lung disease
mRNA vaccine
steroid
vaccine‐induced pneumonitis
Journal
Respirology case reports
ISSN: 2051-3380
Titre abrégé: Respirol Case Rep
Pays: United States
ID NLM: 101631052
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
01
02
2022
revised:
02
03
2022
accepted:
12
03
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
The Pfizer-BioNTech mRNA vaccine (BNT162b2) is an effective and well-tolerated coronavirus disease 2019 (COVID-19) vaccine. However, rare adverse events have been reported. We report two cases of COVID-19 mRNA vaccine-related interstitial lung disease (ILD). A 67-year-old man and a 70-year-old man with underlying ILD presented to our hospital with a few days of fever and respiratory symptoms after receiving the BNT162b2 vaccine. Drug-related pneumonitis due to the COVID-19 mRNA vaccine was diagnosed. One case was diagnosed with lymphocytic alveolitis by bronchoalveolar lavage fluid and transbronchial lung cryobiopsy. Both patients were successfully treated with corticosteroids, and they attended outpatient clinics thereafter. Although the safety and efficacy of COVID-19 vaccines have been established, further studies are needed to estimate long-term data and reports of rare adverse reactions. We present the clinical course of two cases, review previously published case reports on COVID-19 mRNA vaccine-related ILD and discuss the relevant findings.
Identifiants
pubmed: 35355663
doi: 10.1002/rcr2.938
pii: RCR2938
pmc: PMC8942814
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e0938Informations de copyright
© 2022 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.
Déclaration de conflit d'intérêts
None declared.
Références
Allergol Int. 2022 Apr;71(2):251-253
pubmed: 34772608
MMWR Morb Mortal Wkly Rep. 2021 Feb 26;70(8):283-288
pubmed: 33630816
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75
pubmed: 27299520
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Thorax. 2022 Jan;77(1):102-104
pubmed: 34362838
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Intern Med. 2010;49(21):2333-6
pubmed: 21048370
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
QJM. 2022 Jan 5;114(11):805-806
pubmed: 34618126
Respir Res. 2012 May 31;13:39
pubmed: 22651223
Intern Med. 2022 Jan 1;61(1):81-86
pubmed: 34707048
J Infect Chemother. 2022 Jan;28(1):95-98
pubmed: 34580010